PRIMOLUT - N 5mg price in UAE

Overview

Welcome to Dwaey, specifically on PRIMOLUT - N 5mg Tablets page.
This medicine contains an important and useful components, as it consists of Norethisterone.
PRIMOLUT - N 5mg is available in the market in concentration 5mg/Tablet and in the form of Tablets.

SCHERING AG is the producer of PRIMOLUT - N 5mg and it is imported from GERMANY, The most popular alternatives of PRIMOLUT - N 5mg are listed downward .

Mode Of Action

Norethisterone has typical effects of a progestogen and converts the endometrium from the proliferative to the secretory phase. It may also have some oestrogenic, anabolic and androgenic activities, but these may not be significant. Norethisterone delays onset of periods and controls abnormal uterine bleeding. It also has contraceptive effects due to negative feedback inhibition of pituitary gonadotropin thus preventing ovulation.

Indication

Breast cancer
Metropathia haemorrhagica (dysfunctional uterine bleeding)
Premenstrual syndrome
Contraception
Endometriosis
Menorrhagia
Menopausal HRT

Precaution

Hypertension; CVS disease; hepatic impairment; epilepsy; lactation; new onset of migraine-type headache; asthma; renal impairment; history of clinical depression.

Side Effects

Mental depression
cholestatic jaundice
porphyria
epilepsy
migraine
headache
breast discomfort
dizziness
nausea and vomiting
changes in libido
appetite and weight
breakthrough bleeding
changes in menstrual flow
amenorrhoea
oedema
rash
melasma or cholasma
acne
urticaria
abnormal LFTs
moodswings
insomnia
thrombotic and thromoembolic events
optic neuritis
altered lipid profile.

Contra indication

Severe hepatic dysfunction; undiagnosed vaginal bleeding; porphyria; pregnancy; previous idiopathic or current thromboembolism; thromboembolic disease; DVT.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Interaction

Concentration may be reduced by CYP450 inducers (e.g. phenobarbital, phenytoin, carbamazepine, rifampicin, rifabutin, nevirapine, efavirenz, tetracyclines, ampicillin, oxacillin, co-trimoxazole) and ritonavir, nelfinavir (usually inhibitors of CYP450 but have inducing properties when used with steroid hormones). May cause additive fluid retention with NSAIDs, vasodilators. Adjustment in antidiabetic, thyroid hormone and anticoagulant therapy may be required. Potentially Fatal: May increase ciclosporin concentration.